

SCIENTIFIC PUBLICATIONS:

Transferability of real-world data across borders for regulatory and health technology assessment decision-making. Jaksa Ashley, Arena Patrick J., Chan Kelvin K. W., Ben-Joseph Rami H., Jónsson Páll, Campbell Ulka B. *Frontiers in Medicine*. 2022 VOLUME 9. DOI=10.3389/fmed.2022.1073678. www.frontiersin.org/articles/10.3389/fmed.2022.1073678

Resource utilization and charges of patients with and without venous thromboembolism during primary hospitalization and after elective inpatient surgery: a retrospective study. Sepassi A, Chingcuanco F, Gordon R, Meier A, Divino V, DeKoven M, Ben-Joseph R. *J Med Econ*. 2018 Mar 1:1-8.

Use of the SF-36v2 health survey as a screen for risk of major depressive disorder in a US population-based sample and subgroup with chronic pain. Bell JA, daCosta DiBonaventura M, Witt EA, Ben-Joseph R, Reeve BB. *Med Care*. 2017 Feb;55(2):111-116.

Opioid treatment patterns following prescription of immediate-release hydrocodone. Ben-Joseph R, Bell JA, Brixner D, Kansal A, Paramore C, Chitnis A, Holly P, S Burgoyne D. *J Manag Care Spec Pharm*. 2016 Apr;22(4):358-66.

Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone. Ben-Joseph R, Bell JA, Chitnis A, Kansal A, Holly P, Paramore C, Wild H. *J Med Econ*. 2016;19(2):169-80.

Sources of prescription opioids among diagnosed opioid abusers. Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R. *Curr Med Res Opin*. 2015 Apr;31(4):779-84.

Characteristics of high-cost patients diagnosed with opioid abuse. Shei A, Kirson NY, Birnbaum HG, Ben-Joseph R. *Journal of Managed Care Pharmacy*. *J Manag Care Spec Pharm*. 2015 Oct;21(10):902-12.

The burden of undiagnosed opioid abuse among commercially insured individuals. Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R. *Pain Med*. 2015 Apr 30. doi: 10.1111/pme.12768

Medical resource use and costs among pain patients with potential opioid-tolerability issues. Shei A, Birnbaum HG, Ben-Joseph R, Michna E. *J Opioid Manag*. 2014 Sep-Oct;10(5):305-10

Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans. R Ben-Joseph, C Chen, A De, R Wade, D Shah. *J Med Econ*. 2014 Oct;17(10):708-18

Societal economic benefits associated with an extended-release opioid with abuse deterrent technology in the United States. N Kirson, A Shei, A White, H Birnbaum, R Ben-Joseph, L Rossiter, E Michna. *Pain Med*. 2014 Sep;15(9):1450-4

The economic burden of diagnosed opioid abuse among commercially insured individuals. Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R. *Postgrad Med*. 2014 Jul;126(4):53-8

Impact of middle-of-the-night awakenings on health status, activity impairment, and costs. Moline M, DiBonaventura MD, Shah D, Ben-Joseph R. Nature and Science of Sleep 01/2014; 6:101-11

A perspective on the epidemiology of acetaminophen exposure and toxicity in the united states. Blieden M, Paramore LC, Shah D, Ben-Joseph R. Expert Rev Clin Pharmacol. 2014 May;7(3):341-8

Sources of prescription opioids among diagnosed opioid abusers. Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R. Curr Med Res Opin. 2015 Apr;31(4):779-84

Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data. J. Bradford Rice, NY Kirson, A Shei, AG Cummings, K Bodnar, H Birnbaum, R Ben-Joseph. Health Econ Health Policy. 2014 Aug;12(4):435-46

Predicting medication persistence to buprenorphine transdermal system. Joseph V. Pergolizzi, MD; Rami Ben-Joseph, PhD; Chun-Lan Chang, PhD; Gregory Hess, MD. Pain Pract. 2015 Feb;15(2):140-9

Medical cost savings associated with an abuse-deterrent formulation of an extended-release opioid in the US. L Rossiter, NY Kirson, A Shei, A White, H Birnbaum, R Ben-Joseph, E Michna. Journal of Medical Economics 2014;17(4): 279-287

Use of prescription opioids with abuse-deterrent technology to address opioid abuse. E Michna, NY Kirson, A Shei, H Birnbaum, R Ben-Joseph. Curr Med Res Opin 2014 Aug;30(8):1589-98

A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. M Blieden, LC Paramore, D Shah, R Ben-Joseph. Expert Reviews of Clinical Pharmacology 2014;7(3):341-8

US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Pergolizzi J, Hess G, Chang, CC, Ben-Joseph R. Curr Med Res Opin 2014 Aug;30(8):1579-87

Predicting waist circumference from body mass index. Samuel R Bozeman, David C Hoaglin, Tanya M Burton, Chris L Pashos, Rami Ben-Joseph and Christopher S Hollenbeak. BMC Medical Research Methodology 2012;12:115

Daily average consumption of two long-acting opioids: an interrupted time series analysis. R. Amy Puentpatom, Sheryl L. Szeinbach, Larry Ma, Rami Ben-Joseph, Kent H. Summers. American Health and Drug Benefits. Volume 5, Number 1, Epub January/February 2012

Economic impact of potential drug–drug interactions among osteoarthritis patients taking opioids. Joseph V. Pergolizzi, Jr; Sumedha A. Labhsetwar; R. Amy Puenpatom; Rami Ben-Joseph; Robert Ohsfeldt; Kent H. Summers. Pain Pract. 2011 Sep 27.doi: 10.1111/j.1533-2500.2011.00498.x. Pain Pract. 2012 Jan;12(1):33-44

A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. Rubino M, Summers KH, Puenpatom RA, Fu C, Ohsfeldt RL, Ben-Joseph RH. J Manag Care Pharm. 2011 Jun;17(5):367-76

Economic impact of potential drug-drug interactions in opioid analgesics. Summers KH, Puenpatom RA, Ohsfeldt RR, Rajan N, Ben-Joseph RH. J Med Econ. 2011;14(4):390-6

A comparison of daily average consumption of oxycodone controlled release (Oxycontin CR) and oxymorphone extended release (Opana ER) in patients with low back pain. Berner T, Thomson H, Hartry A, Puenpatom RA, Ben-Joseph RH, Szeinbach SL. P&T. 2011 March; 3(36): 139-44

Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Pain Pract. 2011 Jul;11(4):325-36

Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5 years or more. Qayyim Said, Carrie McAdam Marx, J. Sanford Schwartz, Rami Ben-Joseph, Diana I. Brixner. Value in Health. Volume 13, Number 2, 2010

Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pergolizzi JV, Labhsetwar SA; Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Pain Pract. 2011 May-Jun;11(3):230-9. doi: 10.1111/j.1533-2500.2010.00413.x. Epub 2010 Aug 27

Comparing healthcare costs of Medicaid patients with Postherpetic Neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH. J Med Econ. 2010; 13(3): 482-91

Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH. J Med Econ. 2010; 13(3): 472-81

Health economics perspective of the components of the Cardiometabolic Syndrome. Leonardo Tamariz; Ana Palacio; Yadong Yang; Donald Parris; Rami Ben-Joseph; Hermes Florez. Journal of clinical hypertension. 2010;12(7):549-55

Association of cardiometabolic risk factors and prevalent cardiovascular events. Malone DC, Boudreau DM, Nichols GA, Raebel MA, Fishman PA, Feldstein AC, Ben-Joseph RH, Okamoto LJ, Boscoe AN, Magid DJ. MetabSyndrRelatDisord. 2009 Dec;7(6):585-93

Economic outcomes associated with microvascular complications of diabetes mellitus: results from a US claims data analysis. Pelletier EM, Shim B, Ben-Joseph RH, Caro J. Pharmacoeconomics. 2009;27(6):479-90

Health care utilization and costs by metabolic syndrome risk factors. D.M. Boudreau, D.C. Malone, M.A. Raebel, P.A. Fishman, G.A. Nichols, A.C. Feldstei., A.N. Boscoe., R.H. Ben-Joseph, D.J. Magid, L.J. Okamoto. Metabolic Syndrome and Related Disorders. August 2009, 7(4): 305-314

Cardiometabolic risk and health care utilization and cost for Hispanic and non-Hispanic women. Sarah J. Beaton, Scott B. Robinson, Ann Von Worley, Herbert T. Davis, Audra N. Boscoe, Rami Ben-Joseph, and Lynn J. Okamoto. Population Health Management 2009; 12/4: 177-183

The impact of overweight and obesity on the direct medical costs of truck drivers. Bradley C. Martin, Timothy S. Church, Ron Bonnell, Rami Ben-Joseph, Ted Borgstadt. Journal of Occupational & Environmental Medicine. Journal of Occupational and Environmental Medicine. 2009; 51/2: 180-184

Impact of Cardio-Metabolic risk on health care costs before and after an acute myocardial infarction in an elderly population from a health insurance company. H. Florez, A. Palacio, D. Parris, Y. Yang, C. Uribe, R. Ben-Joseph, L. Tamariz. AGS 2008 Annual Meeting, 2008

Prediction of first coronary heart disease and stroke with consideration of adiposity. Wilson PW, Bozeman S, Burton T, Hoaglin D, Ben-Joseph R, Pashos C. Circulation. 2008;118:124-130

Economic costs of obesity to self-insured employers. Emily D. Durden, PhD; Dan Huse, MA; Rami Ben-Joseph, PhD; Bong-Chul Chu, PhD. Journal of Occupational & Environmental Medicine. 50(9):991-997, September 2008

The prevalence of metabolic syndrome in an employed population and the impact on health and productivity, Wayne N. Burton; Chin-Yu Chen; Alyssa B. Schultz; Dee W. Edington. Journal of Occupational & Environmental Medicine. Volume 50, Number 10, October 2008 (Acknowledgement)

Association between cardiometabolic risk factors and body mass index based on diagnosis and treatment codes in an electronic medical record database. Diana Brixner, PhD, RPh; Sameer R. Ghate, BPharm, MSPH; Carrie McAdam-Marx, MS, RPh; Rami Ben-Joseph, PhD; and Qayyim Said, PhD. J Manag Care Pharm. 2008;14(8):756-67

The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Patrick W. Sullivan; Vahram H. Ghushchyan; Rami Ben-Joseph, Qual Life Res. 2008; 17(8)1063-1071

The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the US. Patrick W. Sullivan, Vahram Ghushchyan and Rami Ben-Joseph. Obesity. 2008;16(9)2155-2162

Economic and humanistic outcomes associated with co-morbid type-2 diabetes, high cholesterol, and hypertension among individuals who are overweight or obese. Kannan H, Thompson S, Bolge SC. Journal of Occupational & Environmental Medicine. 50(5):542-549, May 2008 (Acknowledgement)

The medical cost of cardiometabolic risk factor clusters in the United States. Patrick W. Sullivan, Vahram Ghushchyan, Holly R. Wyatt, and James O. Hill. Obesity 2007 15: 3150-3158. (Acknowledgement)

Productivity costs associated with cardiometabolic risk factor clusters in the United States. Sullivan PW, Ghushchyan V, Holly R, Wyatt HR, Wu E, Hill JO. Value in Health, Vol. 10, No. 6. (December 2007), pp. 443-450 (Acknowledgement)

The cost of the metabolic syndrome in the elderly: findings from the cardiovascular health study. Curtis L, Hammill B, Gottdiener J, Schulman K. Diabetes Care 30:2553-2558, 2007 (Acknowledgement)

Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. obesity. Sullivan PW, Ghushchyan V, Holly R, Wyatt HR, Wu E, Hill JO. Obesity 2007; 15(2):511-521. (Acknowledgement)

Predicting the prevalence of cardiometabolic risk factors when clinical data are limited. Hollenbeak CS, Spackman DE, Ben-Joseph RH, Okamoto LJ, Luce BR, Schwartz JS, Sullivan SD. Value in Health. 2007 Jan-Feb;10Suppl 1:S4-S11

Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk Profiles. Caro JJ, O'Brien JA, Hollenbeak CS, Spackman E, Ben-Joseph R, Okamoto LJ, Paramore LC. Value Health. 2007 Jan-Feb;10Suppl 1:S12-20

Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database. Brixner D, Said Q, Kirkness C, Oberg B, Ben-Joseph R, Oderda G. Value Health. 2007 Jan-Feb;10 Suppl 1:S29-36

Age-Specific Impact of Obesity on Prevalence and Costs of Diabetes and Dyslipidemia. Finkelstein EA, Brown DS, Trogon JG, Segel JE, Ben-Joseph RH. Value Health. 2007 Jan-Feb;10Suppl 1:S45-51

National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom. Ameet Bakhai, Marcus D. Flather, Julian R Collinson, Warren Stevens, Charles Norm, Evo Alemao, Robbin Itzler, Rami Ben-Joseph International Journal of Cardiology 91 (2003) 163–172

Cost, morbidity and control of asthma in Hungary: the Hunair study. Herjavec I; Nagy GB; Gyurkovits K; Magyar P; Dobos K; Nagy L; Alemao E; Ben-Joseph RH. J Asthma. 2003 Sep;40(6):673-81

Dosing of inhaled corticosteroids for U.S. pediatric asthmatics in real world settings. Luskin AT; Bukstein D; Ben-Joseph RH. J Asthma. 2001 Dec;38(8):645-55

Inpatient resource utilization in younger (2-5) and older (6-14) asthmatic children in Finland. Valovirta E; Sazonov V; Kaila M; Kajosaari M; Koivikko A; Korhonen K; Linna O; Mäkelä M; Remes K; Ben-Joseph R.H. Eur Respir J. 2002 Aug;20(2):397-402

Persistent asthma: disease control, resource utilization and direct costs. Van Ganse E; Laforest L; Pietri G; Boissel JP; Gormand F; Ben-Joseph RH; Ernst P. Eur Respir J, 20: 260-267 2002

Health care resource use by asthmatics in Croatia. J Oreskovic S; Bozicevic I; Mastilica M; Bakran I; Popovic SJ; Ben-Joseph RH. Asthma, 39(4): 351-8 2002

Dose response of inhaled corticosteroids in mild to moderate asthma. Bousquet J; Ben-Joseph RH; Gould L. Clin Ther, 24(1): 1-20 2002.

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the United Kingdom. Price D; Ben-Joseph R; Zhang Q. Respiratory Medicine. 2001; 95, 1

The relationship between prescribed doses of inhaled corticosteroids and delivered dose in adult asthmatics. Luskin AT; Bukstein D; Ben-Joseph RH. J Asthma, 38(8): 645-55 2001

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Cochrane MG; Bala MV; Eleazer K; Mauskopf J; Ben-Joseph R; CHEST. 2000; 117:542-550

Therapeutic outcomes monitoring: application of pharmaceutical care guidelines to community pharmacy. Grainger-Rousseau TJ, Miralles M, Hepler CD, Segal R, Doty RE, Ben-Joseph R. JAPhA. 1997;NS37(6): 647-661

Cost and quality issues in the management of peptic acid disorder in managed care settings. Segal R, Russell WL, Ben-Joseph R. Clinical Therapeutics. 1996;18(2):319-333

Evaluation of the reliability and validity of a drug use evaluation data collection instrument. Ben-Joseph R., Segal R, Russell W, Oh T. Hospital Formulary. 1995;30:280-3

A Pharmacoeconomics analysis of I. V. histamine2 receptor antagonists use in forty hospitals. Segal R, Oh T, Ben-Joseph R., Russell WL. Hospital Formulary. 1994;29:379-91

Risk for adverse events among patients receiving I.V. histamine2 receptor antagonists. Ben-Joseph R., Segal R, Russell WL. Annals of Pharmacotherapy. 1993;27(12):1532-7

Use of I. V. cimetidine, ranitidine, and famotidine in 40 hospitals in southeastern United States. Segal R, Russell WL, Oh T, Ben-Joseph R., American Journal of Hospital Pharmacy. 1993;50(10):2077-81